Holen Sie sich die Stockscreener-App
0.7243
65.37%
0.2863
Handel nachbörslich:
.66
-0.0643
-8.88%
Cue Biopharma Inc Aktie (CUE) Neueste Nachrichten
12 Health Care Stocks Moving In Wednesday's Intraday SessionAspire Biopharma Holdings (NASDAQ:ASBP), H - Benzinga
Cue Biopharma to present preclinical data on CUE-401 at AAI meeting - Investing.com
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 - The Manila Times
Boston meeting will spotlight Cue Biopharma's new autoimmune drug data - Stock Titan
Cue Biopharma Inc stock (US22966J1060): Does its Immuno-STAT platform deliver the T-cell breakthroug - AD HOC NEWS
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
Cue Biopharma, Inc. Files Form 8-K with SEC Detailing Company and Stock Information (April 13, 2026) 30 - Minichart
CUE stock on track for best day in history — why is retail optimistic? - MSN
Cue Biopharma Shareholders Approve Reverse Stock Split Flexibility - TipRanks
[8-K] Cue Biopharma, Inc. Reports Material Event - Stock Titan
Cue Biopharma receives $7.5M milestone payment from Boehringer Ingelheim - MSN
Cue Biopharma : CUE - 24/7 Wall St.
Exit Recap: Can Cue Biopharma Inc be recession proofCPI Data & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
CUE SEC FilingsCue Biopharma Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cue Biopharma (CUE) SVP and counsel receives 200,000 stock options - Stock Titan
[Form 4] Cue Biopharma, Inc. Insider Trading Activity - Stock Titan
Executive at Cue Biopharma (CUE) granted 100K stock options - Stock Titan
Cue Biopharma Receives $7.5M Milestone Payment From Boehringer Ingelheim - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Cue Biopharma, Inc. (CUE) Discusses CUE-401 R&D Progress and Mechanism for Autoimmune and Inflammatory DiseasesSlideshow (NASDAQ:CUE) 2026-04-09 - Seeking Alpha
Milestone under Cue and Boehringer Ingelheim collaboration - BioWorld News
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement - Bitget
Cue Biopharma to receive $7.5M milestone from Boehringer Ingelheim By Investing.com - Investing.com Australia
Boehringer pays Cue Biopharma $7.5M to progress lead autoimmune asset - The Pharma Letter
Cue Biopharma (CUE) Achieves Preclinical Milestone with Boehring - GuruFocus
Cue Biopharma to receive $7.5 million preclinical milestone payment from Boehringer Ingelheim collaboration and license agreement - marketscreener.com
Cue Biopharma To Receive $7.5 Million Preclinical Milestone Payment From Boehringer Ingelheim Collaboration And License Agreement - TradingView
Cue Biopharma to receive $7.5M milestone from Boehringer Ingelheim - Investing.com
A drug partner just triggered a $7.5M payout for Cue Biopharma - Stock Titan
Cue Biopharma R&D Day: CUE-401 IND Filing Targeted for Q2, Phase 1 Data Expected Late 2026 - Defense World
CUE: CUE-401 is set for phase I trials, backed by strong preclinical data and robust partnership funding - TradingView — Track All Markets
Cue Biopharma, Inc. Files Form 8-K SEC Report for April 2026 – Company Details, Stock Information, and Executive Signature - Minichart
Cue Biopharma says preclinical milestone triggers $7.5 mln payment under Boehringer deal - marketscreener.com
Cue Biopharma Says Preclinical Milestone Triggers $7.5 Mln Payment Under Boehringer Deal - TradingView — Track All Markets
Cue Biopharma Reaches Key Preclinical Milestone With Boehringer - TipRanks
Cue Biopharma to receive $7.5 million milestone payment from Boehringer Ingelheim By Investing.com - Investing.com South Africa
Cue Biopharma to receive $7.5 million milestone payment from Boehringer Ingelheim - Investing.com
Cue Biopharma to receive $7.5M preclinical milestone payment from Boehringer Ingelheim - TradingView — Track All Markets
$7.5M Boehringer milestone advances Cue Biopharma (CUE) B cell program - Stock Titan
CUE Should I Buy - Intellectia AI
CUE.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CUE.O PE Ratio & Valuation, Is CUE.O Overvalued - Intellectia AI
CUE News & Events - Intellectia AI
CUE.O Forecast — Price Prediction for 2026. Should I Buy CUE.O? - Intellectia AI
CUE.O Technical Analysis & Stock Price Forecast - Intellectia AI
[EFFECT] Cue Biopharma, Inc. SEC Filing - Stock Titan
IPO Launch: Is Cue Biopharma Inc benefiting from interest rate changesWeekly Market Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Cue Biopharma Appoints Lucinda Warren Interim CEO - citybiz
Cue Biopharma names Lucinda Warren interim CEO By Investing.com - Investing.com Australia
Cue Biopharma CEO Resignation Leads to 8% Stock Drop - Intellectia AI
CUE stock slips as CEO leaves after just six months in role - MSN
Cue Biopharma Appoints CFO Dr. Kerri-Ann Millar as Interim CEO Following Daniel Passeri’s Departure - geneonline.com
Cue Biopharma Names Lucinda Warren Interim Chief Executive - TipRanks
Cue Biopharma names Lucinda Warren interim CEO - Investing.com
Cue Biopharma IncLucinda Warren to continue as chief financial and business officerSEC filing - marketscreener.com
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):